Anti Inflammatory Drugs Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 110.94 Billion |
| Market Size (2029) | USD 166.81 Billion |
| CAGR (2024 - 2029) | 8.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Anti Inflammatory Drugs Market Analysis
The Anti Inflammatory Drugs Market size is estimated at USD 110.94 billion in 2024, and is expected to reach USD 166.81 billion by 2029, growing at a CAGR of 8.5% during the forecast period (2024-2029).
The anti-inflammatory drugs market is poised for substantial growth, driven by rising incidences of autoimmune, inflammatory, and respiratory conditions and growing research for safer new anti-inflammatory drugs. Conditions like arthritis, allergies, and chronic inflammatory diseases are on the rise, driven by factors such as aging populations and lifestyle changes. Hence, the need for anti-inflammatory drug treatments is expected to increase, boosting the market’s growth over the forecast period.
There are alarming health disparities linked to chronic inflammation, particularly among vulnerable populations. For instance, in January 2024, a study spearheaded by a researcher from the University of Florida’s College of Public Health and Health Professions revealed that individuals grappling with chronic inflammation and living in poverty face a two-fold increased risk of succumbing to heart diseases and an almost three-fold heightened risk of cancer within the subsequent 15 years. Similarly, in 2023, a study spearheaded by Mainous showed 34.6% of US adults exhibiting signs of systemic inflammation. This shows the risk of inflammation and the need for proper treatment, which is expected to drive the market’s growth over the forecast period.
The growing accessibility of anti-inflammatory medications, driven by new product approvals and strategic partnerships aimed at developing innovative therapies, is anticipated to enhance market growth in the coming years. For example, in February 2024, AbbVie Inc. and OSE Immunotherapeutics SA established a strategic collaboration to further the development of OSE-230, a monoclonal antibody targeting chronic and severe inflammation, which was in the pre-clinical stage. This kind of trend is likely to expand the product offerings, contributing positively to market growth during the forecast period.
Therefore, the growing burden of inflammatory conditions and continuous innovations in anti-inflammatory drugs are expected to drive market growth globally. However, the side effects related to anti-inflammatory drugs and patent expiration of various branded drugs are expected to restrain market growth over the forecast period.
Anti Inflammatory Drugs Market Trends
The Asthma Treatment Segment is Expected to Record Significant Growth Over the Forecast Period
Asthma is a chronic respiratory condition characterized by airway inflammation, bronchoconstriction, and increased mucus production. The prevalence of asthma is increasing globally due to various reasons, such as air pollution, occupational chemicals and dust, frequent lower respiratory infections during childhood, tobacco smoking, and other environmental factors. These factors are expected to boost the growth of the anti-inflammatory drugs market.
The World Health Organization (WHO) included asthma in the Global Action Plan for the Prevention and Control of Noncommunicable Diseases (NCDs). The global health landscape is witnessing a concerning trend in respiratory conditions. The update on World Asthma Day 2023 showed the rise in the prevalence of asthma globally, affecting approximately 339 million people. This shows a significantly high burden of asthma worldwide, which is likely to boost the demand for anti-inflammatory drugs such as corticosteroids and propel segmental growth over the forecast period.
The widespread availability of anti-inflammatory drugs for asthma through approvals and launches globally is expected to propel the segment’s growth over the forecast period. For instance, in July 2023, Hormosan Pharma GmbH launched Luforbec 100/6, a combination of a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma where the use of an inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA) is suitable. The launch of a new inhaled corticosteroid and long-acting beta2-agonist combination product expanded treatment options for adult asthma.
North America is Expected to Hold a Significant Share Over the Forecast Period
The anti-inflammatory drugs market in North America, particularly in the United States and Canada, has been experiencing robust growth due to several factors, such as the rising prevalence of inflammatory diseases like rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease, growing research and development investments for new therapies, and company activities such as new product approvals and launches.
The region’s burden of inflammatory diseases is growing, which is expected to increase the need for anti-inflammatory drugs and boost market growth. For instance, according to data published by Statistics Canada in November 2023, 6.28 million people aged 15 years and older had arthritis in 2022 in Canada, compared to 6.08 million in the previous year. Thus, the growing number of arthritis cases in the country is expected to raise the demand for anti-inflammatory drugs, thereby boosting market growth.
Furthermore, new investments in research and development activities for anti-inflammatory therapeutics are expected to boost market growth in the region. For instance, in January 2024, Halia Therapeutics, headquartered in the United States, secured USD 30 million in series C funding to propel its innovative anti-inflammatory therapeutics pipeline. Hence, new investments in R&D are expected to lead to more innovations in the market, thereby boosting its growth over the forecast period.
Therefore, the growing burden of inflammatory diseases and new investments in research and development activities are likely to boost the market’s growth in the region over the forecast period.
Anti-Inflammatory Drugs Industry Overview
The market is fragmented due to the availability of various anti-inflammatory drug manufacturing companies globally. The competitive landscape for the anti-inflammatory drugs market is dynamic and involves several key players, including pharmaceutical companies, biotechnology firms, and generics manufacturers. In addition, this competitive landscape is continuously evolving, driven by innovation, regulatory changes, and shifting market dynamics. Some of the major players in the market include AbbVie Inc., AstraZeneca PLC, F. Hoffmann-La Roche AG, Johnson & Johnson, and Pfizer Inc.
Anti-Inflammatory Drugs Market Leaders
-
Johnson & Johnson
-
Pfizer Inc.
-
AbbVie Inc
-
F. Hoffmann-La Roche AG
-
AstraZeneca PLC
*Disclaimer: Major Players sorted in no particular order
Anti-Inflammatory Drugs Market News
- June 2024: Verona Pharma PLC received approval from the US Food and Drug Administration for Ohtuvayre (ensifentrine), a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre, a pioneering selective dual inhibitor, targets both phosphodiesterase 3 and phosphodiesterase 4 enzymes, merging bronchodilator properties with non-steroidal anti-inflammatory effects in a single molecule.
- March 2024: AbbVie Inc. and Landos Biopharma Inc. entered a definitive agreement under which AbbVie would acquire Landos. Landos' investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair.
Anti Inflammatory Drugs Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Incidences of Autoimmnue and Respiratory Conditions
- 4.2.2 Growing Research for Safer New Anti-Inflammatory Drugs
-
4.3 Market Restraints
- 4.3.1 Side Effects of Anti-Inflammtory Drugs
- 4.3.2 Patent Expiration
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Treatment
- 5.1.1 Arthritis
- 5.1.2 Chronic Obstructive Pulmonary Disease (COPD)
- 5.1.3 Multiple Sclerosis
- 5.1.4 Inflammatory Bowel Disease (IBD)
- 5.1.5 Asthma
- 5.1.6 Tendonitis
- 5.1.7 Other Treatments
-
5.2 By Drug Class
- 5.2.1 Anti-Inflammatory Biologics
- 5.2.2 Non-steroidal Anti Inflammatory Drugs (NSAIDS)
- 5.2.3 Corticosteroids
- 5.2.4 Immune-selective Anti-inflammatory Derivative (ImSAID)
- 5.2.5 Other Drug Classes
-
5.3 By Sales Channel
- 5.3.1 Prescription
- 5.3.2 Over the Counter (OTC)
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Pfizer Inc.
- 6.1.2 Amgen Inc.
- 6.1.3 GSK PLC
- 6.1.4 Johnson & Johnson
- 6.1.5 Novartis AG
- 6.1.6 F. Hoffmann-La Roche AG
- 6.1.7 AbbVie Inc
- 6.1.8 AstraZeneca PLC
- 6.1.9 Merck & Co, Inc.
- 6.1.10 Eli Lily and Company
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAnti Inflammatory Drugs Industry Segmentation
As per the scope of the report, anti-inflammatory drugs are medications that reduce inflammation, which is the body’s natural response to injury or infection. These drugs are used to treat various conditions characterized by inflammation, including arthritis, asthma, inflammatory bowel disease, and other autoimmune disorders.
The anti-inflammatory drugs market is segmented by treatment, drug class, sales channel, and geography. By treatment, the market is segmented into arthritis, chronic obstructive pulmonary disease (COPD), multiple sclerosis, inflammatory bowel disease (IBD), asthma, tendonitis, and other treatments. By drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, immune-selective anti-inflammatory derivatives (ImSAID), and other drug classes. By sales channel, the market is segmented into prescription and over-the-counter (OTC). By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for all the above segments.
| By Treatment | Arthritis | |
| Chronic Obstructive Pulmonary Disease (COPD) | ||
| Multiple Sclerosis | ||
| Inflammatory Bowel Disease (IBD) | ||
| Asthma | ||
| Tendonitis | ||
| Other Treatments | ||
| By Drug Class | Anti-Inflammatory Biologics | |
| Non-steroidal Anti Inflammatory Drugs (NSAIDS) | ||
| Corticosteroids | ||
| Immune-selective Anti-inflammatory Derivative (ImSAID) | ||
| Other Drug Classes | ||
| By Sales Channel | Prescription | |
| Over the Counter (OTC) | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Anti Inflammatory Drugs Market Research FAQs
How big is the Anti Inflammatory Drugs Market?
The Anti Inflammatory Drugs Market size is expected to reach USD 110.94 billion in 2024 and grow at a CAGR of 8.5% to reach USD 166.81 billion by 2029.
What is the current Anti Inflammatory Drugs Market size?
In 2024, the Anti Inflammatory Drugs Market size is expected to reach USD 110.94 billion.
Who are the key players in Anti Inflammatory Drugs Market?
Johnson & Johnson, Pfizer Inc., AbbVie Inc, F. Hoffmann-La Roche AG and AstraZeneca PLC are the major companies operating in the Anti Inflammatory Drugs Market.
Which is the fastest growing region in Anti Inflammatory Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Anti Inflammatory Drugs Market?
In 2024, the North America accounts for the largest market share in Anti Inflammatory Drugs Market.
What years does this Anti Inflammatory Drugs Market cover, and what was the market size in 2023?
In 2023, the Anti Inflammatory Drugs Market size was estimated at USD 101.51 billion. The report covers the Anti Inflammatory Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Anti Inflammatory Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Anti-inflammatory Drugs Industry Report
Statistics for the 2024 Anti-inflammatory Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Anti-inflammatory Drugs analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
